Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy

Cancer

Volumn 86, Issue 8, 1999, Pages 1557-1566

  Kestin, Larry L ^a   Vicini, Frank A ^a   Ziaja, Ellen L ^a   Stromberg, Jannifer S ^a   Frazier, Robert C ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Prostate; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033570030     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2     Document Type: Article

References (36)

1. Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys 1996;36:565-71.
2. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostate cancer: followup. J Urol 1993;149:519-22.
3. Kuban DA, El-Mahdi AM, Schellhammer PF. Prostate specific antigen for pretreatment prediction and post-treatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-16.
4. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
5. Russell KJ, Dunatov C, Hafermann MD, Griffith JT, Polissar L, Pelton J, et al. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 1991;146: 1046-52.
6. Zagars GK, von Eschenbach AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538-48.
7. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32:293-306.
8. Crook JM, Bahadur YA, Bociek RG, Perry GA, Robertson SJ, Esche BA. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systemic biopsy and serum prostate specific antigen. Cancer 1997;79:328-36.
9. Hanks GE, D'Amico A, Epstein BE, Schulteiss TE. Prostate specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 1993;27:125-7.
10. Zeitman AL, Shipley WU. Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer 1993; 71:959-69.
11. American Society for Therapeutic Radiology and Oncology. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
12. American Joint Committee on Cancer. Prostate. In: Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al., editors. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven 1998:203-7.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
15. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
16. D'Amico AV, Whittington R, Malkowicz SB, Schultz D. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:473-7.
17. Ennis RD, Malyszko BK, Heitjan DF, Rubin MA, O'Toole KM, Schiff PB. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:511-7.
18. Hanlon AL, Moore DF, Hanks GE. Modeling postradiation prostate specific antigen level kinetics. Cancer 1998;83: 130-4.
19. Kuban DA, El-Mahdi AM, Schellhammer PF. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? Semin Radiat Oncol 1998;8(2):72-80.
20. PSA nadir levels after radiotherapy for prostate cancer: "a powerful prognostic variable." Oncology (Huntington) 1997; 11(8):1236-9.
21. Schellhammer PF, El-Mahdi AM, Kuban DA, Wright GL. Prostate-specific antigen after radiation therapy. Urol Clin North Am 1997;24:407-14.
22. Aref I, Eapen L, Agboola O, Cross P. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiother Oncol 1998;48:203-7.
23. Critz FA, Levinson AK, Williams WH, Holladay DA. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 1996;14:2893-900.
24. Critz FA, Levinson AK, Williams WH, Holladay DA, Holladay CT. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997;49:322-6.
25. Crook JM, Choan E, Perry GA, Robertson S, Esche BA. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure. Urology 1998;51:566-72.
26. Goad JR, Chang S, Ohori M, Scardino PT. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am 1993;20:727-36.
27. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J Urol 1996;156:450-3.
28. Sartor CI, Strawderman MH, Lin X, Kish KE, McLaughlin PW, Sandler HM. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997;38:941-7.
29. Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 1996;40:159-62.
30. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72:2638-43.
31. Hancock SL, Cox RS, Bagshaw MA. Prostate-specific antigen after radiotherapy for prostate cancer: a reevaluation of longterm biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol 1995;154:1412-7.
32. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients [letter]. J Urol 1994;152:492-5.
33. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997;44:213-21.
34. McLaughlin PW, Sandier HM, Jiroutek MR. Prostate-specific antigen following prostate radiotherapy: how low can you go [letter]? J Clin Oncol 1996;14:2889-92.
35. Chodak GW, Neumann J, Blix G, Sutton H, Farah R. Effect of external beam radiation therapy on serum prostate-specific antigen. Urology 1990;35:288-94.
36. Zagars GK, Pollack A. The fall and rise of prostate-specific antigen. Cancer 1993;72:832-42.